A Phase 1, double-blinded, randomized trial of HY02 for treatment of a subset of Anterior ocular surface inflammation
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Minocycline (Primary)
- Indications Ocular inflammation
- Focus Adverse reactions; First in man
- Sponsors Hovione
- 02 Jun 2017 New trial record
- 25 May 2017 Hovione expects topline results by the end of 2017, as reported in a media release. Dr. John Sheppard will be Clinical Investigator for this trial.